Literature DB >> 12624605

The determinants of left ventricular hypertrophy defined by Sokolow-Lyon criteria in untreated hypertensive patients.

R Antikainen1, T Grodzicki, A J Palmer, D G Beevers, E C Coles, J Webster, C J Bulpitt.   

Abstract

Left ventricular hypertrophy (LVH) measured by electrocardiography (ECG LVH) in hypertensive patients has been shown to be associated with an increased risk of cardiovascular sequelae. Analysis of the determinants predisposing to ECG LVH may be helpful in the prevention of LVH. The Department of Health and Social Security Hypertension Care Computer Project studied 2994 hypertensive patients in whom an electrocardiogram was recorded while not on treatment. LVH was determined as the voltage sum SV1+RV5 or RV6>or=35 mm using Sokolow-Lyon voltage criteria. The relations were determined between the presence of LVH or voltage sum and different variables. Untreated systolic (SBP) and diastolic (DBP) blood pressure and pulse pressure were positively related to the increasing ECG voltage, while body mass index (BMI) and serum cholesterol were inversely related. Blood glucose and age did not correlate significantly. Patients with the presence of ECG LVH were more often men, black people, smokers and users of alcohol. In multiple logistic regression analyses, SBP, DBP, male gender and black race were positively, whereas BMI was negatively related to the presence of LVH. The positive relation of smoking and negative relation of serum cholesterol concentration to the presence of ECG LVH were apparent in men but not in women. This study confirms the adverse association between ECG LVH and SBP and DBP, male gender, black race and decreased BMI. It also addresses the less well-known associations of blood glucose, cholesterol, smoking and alcohol consumption.

Entities:  

Mesh:

Year:  2003        PMID: 12624605     DOI: 10.1038/sj.jhh.1001523

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  7 in total

Review 1.  Increased prevalence of concentric left ventricular hypertrophy in African-Americans: will an epidemic of heart failure follow?

Authors:  Sandeep Kamath; David Markham; Mark H Drazner
Journal:  Heart Fail Rev       Date:  2006-12       Impact factor: 4.214

2.  Racial differences in the association of NT-proBNP with risk of incident heart failure in REGARDS.

Authors:  Nirav Patel; Mary Cushman; Orlando M Gutiérrez; George Howard; Monika M Safford; Paul Muntner; Raegan W Durant; Sumanth D Prabhu; Garima Arora; Emily B Levitan; Pankaj Arora
Journal:  JCI Insight       Date:  2019-06-04

3.  Electrocardiography is Useful to Predict Postoperative Ventricular Arrhythmia in Patients Undergoing Cardiac Surgery: A Retrospective Study.

Authors:  Weichao Li; Weihua Liu; Heng Li
Journal:  Front Physiol       Date:  2022-05-02       Impact factor: 4.755

4.  Estrogen delays the progression of salt-induced cardiac hypertrophy by influencing the renin-angiotensin system in heterozygous proANP gene-disrupted mice.

Authors:  S Jeson Sangaralingham; M Yat Tse; Stephen C Pang
Journal:  Mol Cell Biochem       Date:  2007-08-23       Impact factor: 3.396

5.  Electrocardiographic characteristics in patients with heart failure and normal ejection fraction: A systematic review and meta-analysis.

Authors:  Theodora Nikolaidou; Nathan A Samuel; Carl Marincowitz; David J Fox; John G F Cleland; Andrew L Clark
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-10-11       Impact factor: 1.468

6.  Clinical Characteristics Associated with Electrocardiographic Left Ventricular Hypertrophy in Clinical Normotensives without a History of Hypertension: a Cross-Sectional Study.

Authors:  Hyoeun Lee; Hong Ji Song; Yu-Jin Paek; Kyung-Hee Park; Hye-Mi Noh; Geonhyeok Kim; Young-Gyun Seo
Journal:  Korean J Fam Med       Date:  2019-02-07

7.  Aortic Unfolding Measurement Using Non-Contrast Cardiac CT: Normal Range of Low-Risk Subjects.

Authors:  Ji Won Lee; Byoung Wook Choi
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-09-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.